Clinical trials
Inflammatory Bowel Diseases trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Terminated | 14 |
| Recruiting | 8 |
| Unknown status | 5 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 5 |
| St Vincent's Hospital Melbourne | 5 |
| Amgen | 3 |
| Eli Lilly and Company | 3 |
| Theravance Biopharma | 3 |
| GlaxoSmithKline | 2 |
| Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2 |
| Murdoch Childrens Research Institute | 2 |
| Odyssey Therapeutics | 2 |
| Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammatory Bowel Diseases | 53 |
| Colitis, Ulcerative | 25 |
| Crohn Disease | 21 |
| Colitis | 6 |
| Constriction, Pathologic | 3 |
| Gastrointestinal Diseases | 3 |
| Arthritis, Juvenile | 2 |
| Autoimmune Diseases | 2 |
| Diabetes Mellitus | 1 |
| Gastroenteritis | 1 |
Trials
Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.